Identification of a molecule involved in tumor progression using a patient-derived xenograft model

2014 Fiscal Year Final Research Report

• Project/Area Number: 25670025
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Biological pharmacy
• Research Institution: Osaka University
• Principal Investigator: TSUJIKAWA KAZUTAKE 大阪大学, 薬学研究科(研究院), 教授 (10207376)
• Co-Investigator(Renkei-kenkyūsha): NONOMURA Iwao 大阪大学, 医学系研究科泌尿器科, 教授 (30263263) ; UEMURA Motonao 大阪大学, 医学系研究科泌尿器科, 教授 (40631015) ; FUJITA Kazutoshi 大阪大学, 医学系研究科泌尿器科, 教授 (50636181)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: 淡明型腎細胞がん / 患者がん組織移植マウス / LOXL2 / 悪性化 / 幹細胞

Outline of Final Research Achievements

Clear cell renal cell carcinoma (ccRCC) is the most popular subtype of renal cell carcinoma (RCC). Early-stage ccRCC is curable by clinical surgery, but approximately one-third of all patients present locally metastatic cancer at the time of diagnosis. Therefore, an understanding of the molecular mechanisms of ccRCC progression is crucial for the discovery of molecular-targeted therapies. In the present study, we have established patient-derived xenograft models of ccRCC. The tumors serially transplanted in mice pathohistologically showed high-grade phenotypes. On the other hand, we found LOX-like protein 2 (LOXL2) that is involved in the progression of ccRCC. Our findings suggest that LOXL2 is a potent regulator of integrin α5/β1 protein levels and functions in a tumor-promoting capacity in ccRCC.

Free Research Field

細胞生理学